Search hospitals > Connecticut > New Haven
Smilow Cancer Center/Yale-New Haven Hospital
Claim this profileNew Haven, Connecticut 06510
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
215 reported clinical trials
40 medical researchers
Summary
Smilow Cancer Center/Yale-New Haven Hospital is a medical facility located in New Haven, Connecticut. This center is recognized for care of Skin Cancer, Lung Cancer, Cancer, Breast Cancer, Non-Small Cell Lung Cancer and other specialties. Smilow Cancer Center/Yale-New Haven Hospital is involved with conducting 215 clinical trials across 371 conditions. There are 40 research doctors associated with this hospital, such as Farzana Pashankar, Patricia M Lorusso, Amer M. Zeidan, and Alessandro Santin.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Farzana PashankarYale University7 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
33 reported clinical trials
78 drugs studied
Patricia M LorussoYale Cancer Center6 years of reported clinical research
Expert in Solid Tumors
Expert in Uterine Tumors
27 reported clinical trials
43 drugs studied
Amer M. ZeidanYale Cancer Center4 years of reported clinical research
Expert in Myelodysplastic Syndrome
Expert in T-Lymphoblastic Leukemia/Lymphoma
17 reported clinical trials
27 drugs studied
Alessandro SantinSmilow Cancer Hospital at Yale New Haven5 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
17 reported clinical trials
25 drugs studied
Clinical Trials running at Smilow Cancer Center/Yale-New Haven Hospital
Lung Cancer
Skin Cancer
Multiple Myeloma
Ovarian Cancer
Non-Small Cell Lung Cancer
Uterine Tumors
Cancer
Squamous Cell Carcinoma
Breast Cancer
Prostate Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Thoracotomy vs Thoracoscopy
for Metastatic Osteosarcoma
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.
Recruiting2 awards Phase 37 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Smilow Cancer Center/Yale-New Haven Hospital?
Smilow Cancer Center/Yale-New Haven Hospital is a medical facility located in New Haven, Connecticut. This center is recognized for care of Skin Cancer, Lung Cancer, Cancer, Breast Cancer, Non-Small Cell Lung Cancer and other specialties. Smilow Cancer Center/Yale-New Haven Hospital is involved with conducting 215 clinical trials across 371 conditions. There are 40 research doctors associated with this hospital, such as Farzana Pashankar, Patricia M Lorusso, Amer M. Zeidan, and Alessandro Santin.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.